Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the second publication of its research results on the use of cannabinoids (CBD’s) to treat various cancers. The peer-reviewed research article, “Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids”, was published on April 24thin Frontiers in Oncology.
The article can be viewed at https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full.
Cannabis Science’s latest article explores the potential of combination approaches employing CBDs with radiotherapy and smart biomaterials toward enhancing therapeutic efficacy during treatment of pancreatic and lung cancers. The significance of these research findings, considerations for further research, and a viable roadmap to clinical translation are discussed in this article.
"This second publication reflects our ongoing work and we continue to examine the effect of CBDs with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the U.S. Food and Drug Administration (FDA). As we continue this work we will expand our pharmaceutical development program from farm to bedside," stated Dr. Allen A. Herman, Cannabis Science’s Chief Medical Officer (CMO).
The innovative drug delivery strategy for CBDs is consistent with the three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of CBDs being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions.
The initial results of Cannabis Science’s current research were published in September 2017 in Frontiers in Oncology. This peer-reviewed article, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, has been viewed more than 11,000 times, and has more views than 96% of all Frontiers’ articles. The first article addresses drug delivery and highlights an innovative strategy to transport CBDs directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.
Frontiers publishes several of the most-cited open-access journals in the world, and is one of the largest and fastest-growing open-access publishers with millions of monthly page views. Compared to all journals (subscription and open-access), Frontiers’ journals rank 1stmost cited in four categories, namely Neurosciences, Psychology, Multidisciplinary Psychology, and Plant Sciences.
To view Cannabis Science’s first article in Frontiers in Oncology:
To view the first article’s impact:
“This strong – and increasing – level of interest by our colleagues validates the importance of our research,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, Chief Executive Officer, and Co-founder. “We believe that our Company, along with our collaborators, are helping to better understand the science of cannabinoid utilization in cancer therapeutics and novel ways of drug delivery and targeting. In so doing, we expect to develop medicines that can positively impact so many patients in the U.S. and worldwide.”
Cannabis Science’s research forms part of a pipeline from research to scientific publication that the Company is developing with its research partners, and demonstrates the Company’s strong commitment to science in its pharmaceutical development program. “We developed this pipeline to ensure that Cannabis Science’s research work reaches the scientific community and the public in a timely fashion,” stated Mr. Dabney.
Cannabis Science’s funded research currently focuses on the clinical applications of CBDs in cancer treatment and pain management. The Company’s research will expand to investigate the effectiveness of CBD treatment in an increasing array of cancers, especially difficult to treat cancers and those with high fatality rates; develop novel targeted delivery methods in the use of CBDs, and – with advances in bioinformatics, computer science, and pharmacology – explore the mechanisms of action of CBDs in the management of disease.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, the characterization of medicines, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.